Acute Lymphoid Leukemia - Healing Genes

Acute Lymphoid Leukemia

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL

Phase 2 Study of Humanized CD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19) for Very High-Risk Subsets of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Phase 1


Doctors at the Children’s Hospital of Philadelphia seek to enroll patients in a clinical trial to treat newly diagnosed B-ALL patients predicted to have an exceedingly poor outcome with conventional chemotherapy, in high-risk first relapse, or and in second or greater relapse that tests positive for CD19+ antigens.

The investigatory treatment, a gene-modified immunotherapy, withdraws immune T-cells from the patient and, utilizing gene editing, the white blood cells will be trained to target their cancer cells. Then the modified T-cells will be infused to the patient after a course of chemotherapy. Follow up lasts at least 1 year.


  • Be 1 to 29 years of age
  • Be diagnosed with one of the eligible cancers, with DNA tests to confirm subtype required
  • Be HIV negative


  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. Have blood drawn, immune cells separated and blood cells returned (leukapheresis)
  3. After lab modification time, the patient will be admitted to the hospital and receive chemotherapy over 3 to 5 days.
  4. The gene-edited immune cells will be infused.
  5. Recovery in the hospital.
  6. Follow up continues for at least 1 year.

The study site is at the Children’s Hospital of Pennsylvania in Philadelphia, PA. Map.

Mia Benson-Smith  |  267-426-0762  |  [email protected]
Claire White  |  [email protected]
University of Pennsylvania
The Children’s Hospital of Philadelphia
Or go online:



Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader